Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 March 2008, Vol. 111, No. 6, pp. 3276-3285.
Prepublished online as a Blood First Edition Paper on October 9, 2007; DOI 10.1182/blood-2007-08-106286.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-08-106286v1
111/6/3276    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujii, H.
Right arrow Articles by Schultz, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujii, H.
Right arrow Articles by Schultz, K. R.
Related Collections
Right arrow Transplantation
Right arrow Free Research Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

TRANSPLANTATION

Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group

Hisaki Fujii1, Geoff Cuvelier1, Kevin She1, Soudabeh Aslanian1, Hiromi Shimizu1, Amina Kariminia1, Mark Krailo2, Zhengjia Chen3, Rob McMaster4, Axel Bergman4, Frederick Goldman5, Stephen A. Grupp6, Donna A. Wall7, Andrew L. Gilman8, and Kirk R. Schultz1

1 Children's Oncology Group, Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Pediatrics, BC Children's Hospital/University of British Columbia, Vancouver, BC; 2 Children's Oncology Group, Department of Preventative Medicine, University of Southern California, Los Angeles; 3 Children's Oncology Group Operations Center, Arcadia, CA; 4 Medical Genetics, University of British Columbia, Vancouver, BC; 5 University of Iowa, Iowa City; 6 Division of Pediatric Oncology, Childrens Hospital of Philadelphia, PA; 7 Methodist Children's Hospital of South Texas, Texas Transplant Institute, San Antonio; and 8 University of North Carolina at Chapel Hill

Numerous chronic graft-versus-host disease (cGVHD) biomarkers have been identified in limited, single-institution studies without validation. We hypothesized that plasma-derived biomarkers could diagnose, classify, and evaluate response in children with cGVHD. We performed a concomitant analysis of a number of known and predicted peripheral blood cGVHD biomarkers from a Children's Oncology Group (COG) phase 3 cGVHD therapeutic trial. A total of 52 newly diagnosed patients with extensive cGVHD were compared for time of onset after blood and marrow transplantation (BMT) (early, 3-8 months; late, ≥ 9 months) with 28 time-matched controls with no cGVHD (early, 6 months after BMT; late, 12 months after BMT). Soluble B-cell activation factor (sBAFF), anti-dsDNA antibody, soluble IL-2 receptor alpha (sIL-2R{alpha}), and soluble CD13 (sCD13) were elevated in patients with early-onset cGVHD compared with controls. sBAFF and anti-dsDNA were elevated in patients with late-onset cGVHD. Some of the biomarkers correlated with specific organ involvement and with therapeutic response. These 4 biomarkers had high specificity with higher sensitivity in combination. Changes in biomarker concentrations with immune reconstitution after transplantation significantly affected interpretation of results. The identified biomarkers have the potential for improved classification, early response evaluation, and direction of cGVHD treatment, but require validation in larger studies. This study is registered at www.cancer.gov/clinicaltrials as no. COG-ASCT0031.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
S. Sarantopoulos, K. E. Stevenson, H. T. Kim, C. S. Cutler, N. S. Bhuiya, M. Schowalter, V. T. Ho, E. P. Alyea, J. Koreth, B. R. Blazar, et al.
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
Blood, April 16, 2009; 113(16): 3865 - 3874.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020